Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
08/10/2026 13:14
BRIEF-Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA) Oct 8 (Reuters) - Scholar Rock Holding Corporation SRRK.O:
SCHOLAR ROCK RESUBMITS APITEGROMAB MARKETING AUTHORISATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENCY (EMA) FOR TREATMENT OF CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA)
SCHOLAR ROCK HOLDING CORPORATION - ANTICIPATES CHMP OPINION ON APITEGROMAB MAA IN H1 2027
Source text: ID:nBw2WFMzZa
Further company coverage: SRRK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up